Application of Nanotechnology for Cancer Treatment

  • Monika Verma
  • Promila Sheoran
  • Ashok Chaudhury


Cancer has become a big threat to mankind worldwide. This disease is the second most common disease with maximum mortality. According to the recent report from ICMR, 1300 people die every day in India because of cancer. Despite having good progress in diagnosis as well as in treatment, cancer is still a big nuance to our society. It has become more and more clearer in the recent times and evident that the development of new drugs alone is not enough for ensuring progress in drug therapy. This is why to achieve high intra-tumor drug concentration along with minimum exposure of drugs to normal tissue is the most important goal of anticancer drug delivery. These problems can be overcome by using nanoparticles for their delivery. It enhances the permeability and retention onto the tumor cells and not onto healthy cells. It also helps in delivering the slow and controlled release to the targeted cells. Drug carriers in nanoscale offer the chances of enhancing the therapeutic index of drug molecules by diminishing their toxicity against physiological tissues and achieving controlled therapeutic levels of the drug for a long time. It would minimize the concentration of drug intake and maximize the overall profile of absorption, biodistribution, metabolism, and excretion (ADME) profile.



This work was supported by Department of Science and Technology, Ministry of Science and Technology, Government of India, New Delhi for providing financial assistance under Nano Mission program vide Sanction Letter # SR/NM/PG-01/2007 and University Grants Commission, New Delhi, India vide Sanction Letter # F-3-18/2009 dated 31st March, 2009 and Sanction Letter # F-3-4/2016/DRS-II (SAP-II) dated 1st April 2016 under Special Assistance Program (SAP) DRS-I and SAP DRS-II Program.


  1. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:1605–1621CrossRefGoogle Scholar
  2. Ali I, Rahis-Uddin SK, Rather MA, Wani WA, Haque A (2011) Advances in nano drugs for cancer chemotherapy. Curr Cancer Drug Targets 11(2):135–146CrossRefPubMedGoogle Scholar
  3. Arora P, Sindhu A, Dilbaghi N, Chaudhury A (2011) Biosensors as innovative tools for the detection of food borne pathogens. Biosens Bioelectron 28(1):1–12CrossRefGoogle Scholar
  4. Arora P, Sindhu A, Dilbaghi N, Chaudhury A, Rajakumar G, Rahuman AA (2012) Nano-regenerative medicine towards clinical outcome of stem cell and tissue engineering in humans. J Cell Mol Med 16(9):1991–2000CrossRefPubMedPubMedCentralGoogle Scholar
  5. Arora P, Sindhu A, Kaur H, Dilbaghi N, Chaudhury A (2013) An overview of transducers as platform for the rapid detection of foodborne pathogens. Appl Microbiol Biotechnol 97(5):1829CrossRefPubMedGoogle Scholar
  6. Bakers RJ (2009) Dendrimer-based nanoparticles for cancer therapy. Hematology 1:708–719CrossRefGoogle Scholar
  7. Bansal P, Duhan JS, Gahlawat SK (2014) Biogenesis of nanoparticles. Afr J Biotechnol 13(28):2778–2785CrossRefGoogle Scholar
  8. Bao H, Zhang Q, Xu H, Yan Z (2016) Effects of nanoparticle size on antitumor activity of 10-hydroxycamptothecin-conjugated gold nanoparticles: in vitro and in vivo studies. Int J Nanomedicine 7(11):929–940Google Scholar
  9. Barenholz Y (2012) Doxil -the first FDA-approved nano-drug: lessons learned. J Control Release 160(2):117–134CrossRefPubMedGoogle Scholar
  10. Byrne J, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60(14):1615–1626CrossRefPubMedGoogle Scholar
  11. Cai W, Chen X (2007) Nano platforms for targeted molecular imaging in living subjects. Small 3:1840–1854CrossRefPubMedGoogle Scholar
  12. Cho CS, Cho KY, Park IK, Kim SH, Sasagawa T, Uchiyama M, Akaike T (2001) Receptor mediated delivery of all trans-retinoic acid to hepatocyte using poly(L-lactic acid) nanoparticles coated with galactose-carrying polystyrene. J Control Release 77(1–2):7–15CrossRefPubMedGoogle Scholar
  13. Divakar P, Kumar D, Praveen C, Sowmya C, Suryaprakash Reddy C (2013) Formulation and in vitro evaluation of liposomes containing metformin hydrochloride. Int J Res Pharm Biomed Sci 4(2):479–485Google Scholar
  14. Duangjit S, Opanasopit P, Rojanarata T, Ngawhirunpat T (2011) Characterization and in vitro skin permeation of meloxicam-loaded liposomes versus transfersomes. J Drug Deliv 2011:418316CrossRefPubMedGoogle Scholar
  15. Duangjit S, Opanasopit P, Rojanarata T, Ngawhirunpat T (2013) Evaluation of meloxicam-loaded cationic transfersomes as transdermal drug delivery carriers. AAPS Pharm Sci Tech 14:133–140CrossRefGoogle Scholar
  16. Dubey V, Mishra D, Jain NK (2007) Melatonin loaded ethanolic liposomes: physicochemical characterization and enhanced transdermal delivery. Eur J Pharm Biopharm 67(2):398–405CrossRefPubMedGoogle Scholar
  17. El-Kassas H, Attia AA (2014) Bactericidal application and cytotoxic activity of biosynthesized silver nanoparticles with an extract of the red seaweed Pterocladiella capillacea on the HepG2 cell line. Asian Pac J Cancer Prev 15:1299–1306CrossRefPubMedGoogle Scholar
  18. Elzoghby AO, Abd-Elwakil MM, Abd-Elsalam K, Elsayed MT, Hashem Y, Mohamed O (2016) Natural polymeric nanoparticles for brain-targeting: implications on drug and gene delivery. Curr Pharm Des 22:3305–3323CrossRefPubMedGoogle Scholar
  19. Estanqueiro M, Amaral MH, Conceiçao J, Sousa Lobo JM (2015) Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B Biointerfaces 126:631–648CrossRefPubMedGoogle Scholar
  20. Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63(3):136–151CrossRefPubMedGoogle Scholar
  21. Feng Q, Sun J, Jiang X (2016) Microfluidics-mediated assembly of functional nanoparticles for cancer-related pharmaceutical applications. Nano Scale.
  22. Gao Z, Lukyanov A, Singhal A, Torchilin V (2002) Diacyllipid-polymer micelles as nano- carriers for poorly soluble anticancer drugs. Nano Lett 2(9):979–982CrossRefGoogle Scholar
  23. Giri S, Karakoti A, Graham RP, Maguire JL, Reilly CM, Seal S, Rattan R, Shridhar V (2013) Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. PLoS One 81:545–578Google Scholar
  24. Glavas-Dodov M, Fredro-Kumbaradzi E, Goracinova K, Calis S, Simonoska M, Hincal AA (2003) 5-Fluorouracil in topical liposome gels for anticancer treatment-formulation and evaluation. Acta Pharma 53(4):241–250Google Scholar
  25. Godin B, Touitou E (2003) Ethosomes: new prospects in transdermal delivery. Crit Rev Ther Drug Carrier Syst 20(1):63–102CrossRefPubMedGoogle Scholar
  26. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803CrossRefPubMedGoogle Scholar
  27. Gupta A, Aggarwal G, Singla S, Arora R (2012) Transfersomes: a novel vesicular carrier for enhanced transdermal delivery of sertraline: development, characterization, and performance evaluation. Sci Pharm 80(4):1061–1080CrossRefPubMedPubMedCentralGoogle Scholar
  28. Gupta B, Chakraborty S, Saha S, Chandel S, Baranwal A, Banerjee M, Chatterjee M, Chaudhury A (2016) Antinociceptive properties of shikonin: in vitro and in vivo studies. Canad J Physiol Pharmacol.
  29. Hayashi M, Silanikove N, Chang X, Ravi R, Pham V, Baia G, Paz K, Brait M, Sidransky D (2015) Milk derived colloid as a novel drug delivery carrier for breast cancer. Cancer Biol Ther 16(8):1184–1193CrossRefPubMedPubMedCentralGoogle Scholar
  30. Hofferberth SC, Grinstaff MW, Colson YL (2016) Nanotechnology applications in thoracic surgery. Eur J Cardiothorac Surg 50(1):6–16. PMID 26843431CrossRefPubMedPubMedCentralGoogle Scholar
  31. Hou XY, Jiang G, Yang CS, Tang JQ, Wei ZP, Liu YQ (2016) Application of nanotechnology in the diagnosis and therapy of hepatocellular carcinoma. Recent Pat Anticancer Drug Discov 11(3):322–331. PMID:26955964CrossRefPubMedGoogle Scholar
  32. Irfan M, Verma S, Ram A (2012) Preparation and characterization of Ibuprofen loaded transferosome as a novel carrier for transdermal drug delivery system. Asian J Pharm Clin Res 5:162–165Google Scholar
  33. Jana NR, Gearheart L, Murphy CJ (2001) Wet chemical synthesis of high aspect ratio cylindrical gold nanorods. J Phys Chem B 105:4065–4067CrossRefGoogle Scholar
  34. Jing L, Liang X, Li X, Lin L, Yang Y, Yue X, Dai Z (2014) Mn-porphyrin conjugated au nanoshells encapsulating doxorubicin for potential magnetic resonance imaging and light triggered synergistic therapy of cancer. Theranostics. 2014 4(9):858–871. CrossRefPubMedPubMedCentralGoogle Scholar
  35. Katiyar SS, Muntimadugu E, Rafeeqi TA, Domb AJ, Khan W (2015) Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment. Drug Deliv 2:1–9CrossRefGoogle Scholar
  36. Kaur P, Thakur R, Chaudhury A (2012) An in vitro study of the antifungal activity of silver/chitosan nanoformulations against important seed borne pathogens. Int J Sci Technol Res 1(6):83–86Google Scholar
  37. Kaur P, Chaudhury A, Thakur R (2013) Synthesis of chitosan-silver nanocomposites and their antibacterial activity. Int J Sci Eng Res 4(4):869Google Scholar
  38. Kaur P, Thakur R, Barnela M, Chopra M, Manuja A, Chaudhury A (2014) Synthesis, characterization and in vitro evaluation of cytotoxicity and antimicrobial activity of chitosan–metal nanocomposites. J Chem Technol Biotech.
  39. Kaur P, Thakur R, Chaudhury A (2016) Biogenesis of copper nanoparticles using peel extract of Punica granatum and their antimicrobial activity against opportunistic pathogens. Green Chem Lett Rev 9(1):33–38CrossRefGoogle Scholar
  40. Koziorowski J, Stanciu AE, Gómez-Vallejo V, Llop J (2016) Radiolabeled nanoparticles for cancer diagnosis and therapy. Anticancer Agents Med Chem. 17 333–354 PMID:26899184CrossRefPubMedGoogle Scholar
  41. Kulhari A, Sheorayan A, Chaudhury A (2013) Targeted chemotherapeutics: an overview of recent progress in effectual cancer treatment. Pharmacologia 4(9):535–552CrossRefGoogle Scholar
  42. Malam Y, Loizidou M, Seifalian AM (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30(11):592–599CrossRefPubMedGoogle Scholar
  43. Martins AF, Follmann HD, Monteiro JP, Bonafé EG, Nocchi S, Silva CT, Nakamura CV, Girotto EM, Rubira AF, Muniz EC (2015) Polyelectrolyte complex containing silver nanoparticles with antitumor property on Caco-2 colon cancer cells. Int J Biol Macromol 79:748–755 S0141-8130(15)00377-3CrossRefPubMedGoogle Scholar
  44. Mittal AK, Tripathy D, Choudhary A, Aili PK, Chatterjee A, Singh IP, Banerjee UC (2015) Bio-synthesis of silver nanoparticles using Potentilla fulgens Wall. ex Hook and its therapeutic evaluation as anticancer and antimicrobial agent. Mater Sci Eng C Mater Biol Appl 1(53):120–127CrossRefGoogle Scholar
  45. Mohamed S, Parayath NN, Taurin S, Greish K (2014) Polymeric nano-micelles: versatile platform for targeted delivery in cancer. Ther Deliv 5(10):1101–1121CrossRefPubMedGoogle Scholar
  46. Mohammad F, Yusof NA (2014) Doxorubicin-loaded magnetic gold nanoshells for a combination therapy of hyperthermia and drug delivery. J Colloid Interface Sci 434:89–97CrossRefPubMedGoogle Scholar
  47. Mousa SA, Bharali DJ (2011) Nanotechnology-based detection and targeted therapy in cancer. Nano-Bio Paradigms Appl Cancers (Basel) 3(3):2888–2903CrossRefGoogle Scholar
  48. Office of Technology and Industrial Relations of the US National Cancer Institute (OTIR) (2006).
  49. Ooya T, Lee J, Park K (2004) Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization, and hydrotropic solubilization of paclitaxel. Bioconjug Chem 15:1221–1229CrossRefPubMedGoogle Scholar
  50. Park K (2007) Nanotechnology: what it can do for drug delivery. J Control Release 120:1–3CrossRefPubMedPubMedCentralGoogle Scholar
  51. Patra S, Mukherjee S, Barui AK, Ganguly A, Sreedhar B, Patra CR (2015) Green synthesis, characterization of gold and silver nanoparticles and their potential application for cancer therapeutics. Mater Sci Eng C Mater Biol Appl 53:298–309CrossRefPubMedGoogle Scholar
  52. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751–760CrossRefGoogle Scholar
  53. Praetorius NP, Mandal TK (2007) Engineered nanoparticles in cancer therapy. Recent Pat Drug Deliv Formul 1(1):37–51CrossRefPubMedGoogle Scholar
  54. Reimer P, Tombach B (1998) Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Eur Radiol 8(7):1198–1204CrossRefPubMedGoogle Scholar
  55. Schnyder A, Krahenbuhl S, Drewe J, Huwyler J (2005) Targeting of daunomycin using bio-tinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J Drug Target 13(5):325–335CrossRefPubMedGoogle Scholar
  56. Singh SY, Aher SS, Saudagar RB (2015) Ethosomes-novel drug delivery system. Res J Top Cosmet Sci 6(1):7–14CrossRefGoogle Scholar
  57. Sun Y, Xia Y (2002) Shape-controlled synthesis of gold and silver nanoparticles. Science 298:2176–2179CrossRefPubMedGoogle Scholar
  58. Touitou E, Godin B, Dayan N, Weiss C, Piliponsky A, Levi-Schaffer F (2001) Intracellular delivery mediated by an ethosomal carrier. Biomaterials 22:3053–3059CrossRefPubMedGoogle Scholar
  59. Vanna S, Nicolino P, Mario S (2014) Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine 9:467–483Google Scholar
  60. Walve JR, Bakliwal SR, Rane BR, Pawar SP (2011) Transferomes: a surrogated carrier for transdermal drug delivery system. Int J Appl Biol Pharm Tech 2:1. ISSN 0976-4550Google Scholar
  61. Wang AZ, Bagalkot V, Vasilliou C, Gu F, Alexis F, Zhang L, Shaikh M, Yuet K, Cima M, Langer R, Kantoff P, Bander N, Jon S, Farokhzad O (2008) Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. Chem Med Chem 3:1311–1315CrossRefPubMedGoogle Scholar
  62. Wang X, Li J, Wang Y et al (2009) HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano 3:3165–3174CrossRefPubMedPubMedCentralGoogle Scholar
  63. Wong HL, Rauth AM, Bendayan R, Wu XY (2007) In vivo evaluation of a new polymer– lipid hybrid nanoparticle (Pln) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm 65(3):300–308CrossRefPubMedGoogle Scholar
  64. Wu C, Yu C, Chu M (2011) A gold nanoshell with a silica inner shell synthesized using liposome templates for doxorubicin loading and near-infrared photothermal therapy. Int J Nanomedicine 6:807–813PubMedPubMedCentralGoogle Scholar
  65. Wunderbaldinger P, Josephson L, Bremer C, Moore A, Weissleder R (2002) Detection of lymph node metastases by contrast-enhanced MRI in an experimental model. Magn Reson Med 47:292–297CrossRefPubMedGoogle Scholar
  66. Zhang H, Hu H, Zhang H, Dai W, Wang X, Wang X, Zhang Q (2015) Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis. Nanoscale 7(24):10790–10800CrossRefPubMedGoogle Scholar
  67. Zhao Y, Pang B, Luehmann H, Detering L, Yang X, Sultan D, Harpstrite S, Sharma V, Cutler CS, Xia Y, Liu Y (2016) Gold nanoparticles doped with 199 Au atoms and their use for targeted cancer imaging by SPECT. Adv Healthc Mater 5(8):928–935CrossRefPubMedPubMedCentralGoogle Scholar
  68. Zhuang L, Kai C, Davis C, Sherlock S, Cao Q, Chen X, Dai H (2016) Drug delivery with carbon nanotubes for in vivo cancer treatment. 68 6652–6660 PMID:18701489Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Monika Verma
    • 1
  • Promila Sheoran
    • 1
  • Ashok Chaudhury
    • 1
  1. 1.Department of Bio & Nano Technology, Bio & Nano Technology CentreGuru Jambheshwar University of Science & TechnologyHisarIndia

Personalised recommendations